Compare Elder Pharma with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs SUVEN LIFESCIENCES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA SUVEN LIFESCIENCES ELDER PHARMA/
SUVEN LIFESCIENCES
 
P/E (TTM) x -0.2 19.4 - View Chart
P/BV x 0.1 3.9 2.6% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 ELDER PHARMA   SUVEN LIFESCIENCES
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
SUVEN LIFESCIENCES
Mar-19
ELDER PHARMA/
SUVEN LIFESCIENCES
5-Yr Chart
Click to enlarge
High Rs380338 112.5%   
Low Rs188169 111.0%   
Sales per share (Unadj.) Rs491.252.1 942.3%  
Earnings per share (Unadj.) Rs-3.26.8 -46.6%  
Cash flow per share (Unadj.) Rs14.48.6 168.1%  
Dividends per share (Unadj.) Rs01.50 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs376.565.3 576.7%  
Shares outstanding (eoy) m20.54127.28 16.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.64.9 11.9%   
Avg P/E ratio x-89.337.1 -240.5%  
P/CF ratio (eoy) x19.729.6 66.6%  
Price / Book Value ratio x0.83.9 19.4%  
Dividend payout %022.0 0.0%   
Avg Mkt Cap Rs m5,83332,272 18.1%   
No. of employees `000NA1.1 0.0%   
Total wages/salary Rs m2,179661 329.6%   
Avg. sales/employee Rs ThNM6,132.2-  
Avg. wages/employee Rs ThNM611.1-  
Avg. net profit/employee Rs ThNM803.5-  
INCOME DATA
Net Sales Rs m10,0896,635 152.1%  
Other income Rs m257242 105.9%   
Total revenues Rs m10,3466,877 150.4%   
Gross profit Rs m-7921,604 -49.4%  
Depreciation Rs m361221 163.2%   
Interest Rs m2,75638 7,311.1%   
Profit before tax Rs m-3,6531,587 -230.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m125718 17.4%   
Profit after tax Rs m-65869 -7.5%  
Gross profit margin %-7.824.2 -32.5%  
Effective tax rate %-3.445.2 -7.6%   
Net profit margin %-0.613.1 -4.9%  
BALANCE SHEET DATA
Current assets Rs m9,2406,232 148.3%   
Current liabilities Rs m9,9981,490 670.9%   
Net working cap to sales %-7.571.5 -10.5%  
Current ratio x0.94.2 22.1%  
Inventory Days Days4686 53.6%  
Debtors Days Days6083 72.6%  
Net fixed assets Rs m10,1244,043 250.4%   
Share capital Rs m206127 161.6%   
"Free" reserves Rs m5,5828,183 68.2%   
Net worth Rs m7,7348,310 93.1%   
Long term debt Rs m4,88918 27,466.3%   
Total assets Rs m22,88210,389 220.3%  
Interest coverage x-0.343.1 -0.8%   
Debt to equity ratio x0.60 29,513.4%  
Sales to assets ratio x0.40.6 69.0%   
Return on assets %11.88.7 134.7%  
Return on equity %-0.810.5 -8.1%  
Return on capital %22.319.5 114.3%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m3075,622 5.5%   
Fx outflow Rs m1251,799 7.0%   
Net fx Rs m1813,822 4.7%   
CASH FLOW
From Operations Rs m11,754356 3,306.4%  
From Investments Rs m-561-279 201.2%  
From Financial Activity Rs m-6,762-225 3,003.9%  
Net Cashflow Rs m4,432-148 -2,990.4%  

Share Holding

Indian Promoters % 39.6 63.4 62.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 0.0 -  
FIIs % 16.8 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 36.5 98.9%  
Shareholders   16,479 37,287 44.2%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   DR. DATSONS LABS  DISHMAN PHARMA  J.B.CHEMICALS  NATCO PHARMA  BIOCON   

Compare ELDER PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFE Announces Quarterly Results (3QFY19); Net Profit Down 27.1% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUVEN LIFE has posted a net profit of Rs 252 m (down 27.1% YoY). Sales on the other hand came in at Rs 1 bn (down 21.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

SUVEN LIFE Announces Quarterly Results (2QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, SUVEN LIFE has posted a net profit of Rs 180 m (down 43.3% YoY). Sales on the other hand came in at Rs 895 m (down 16.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 5-YR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS